CL2016003076A1 - Péptidos como agonistas de la oxitocina - Google Patents

Péptidos como agonistas de la oxitocina

Info

Publication number
CL2016003076A1
CL2016003076A1 CL2016003076A CL2016003076A CL2016003076A1 CL 2016003076 A1 CL2016003076 A1 CL 2016003076A1 CL 2016003076 A CL2016003076 A CL 2016003076A CL 2016003076 A CL2016003076 A CL 2016003076A CL 2016003076 A1 CL2016003076 A1 CL 2016003076A1
Authority
CL
Chile
Prior art keywords
peptides
oxytocin agonists
oxytocin
agonists
Prior art date
Application number
CL2016003076A
Other languages
English (en)
Inventor
Caterina Bissantz
Konrad Bleicher
Kanchan Chakraborty
Christophe Grundschober
Goutam Saha
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2016003076A1 publication Critical patent/CL2016003076A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/16—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

<p>S</p>
CL2016003076A 2014-06-06 2016-11-29 Péptidos como agonistas de la oxitocina CL2016003076A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14171440 2014-06-06

Publications (1)

Publication Number Publication Date
CL2016003076A1 true CL2016003076A1 (es) 2017-08-11

Family

ID=50932985

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016003076A CL2016003076A1 (es) 2014-06-06 2016-11-29 Péptidos como agonistas de la oxitocina

Country Status (16)

Country Link
US (1) US20170081368A1 (es)
EP (1) EP3152225B1 (es)
JP (1) JP6535688B2 (es)
KR (1) KR20170004014A (es)
CN (1) CN106459156A (es)
AU (1) AU2015270564A1 (es)
CA (1) CA2950493A1 (es)
CL (1) CL2016003076A1 (es)
CR (1) CR20160562A (es)
EA (1) EA030296B1 (es)
IL (1) IL248625A0 (es)
MX (1) MX2016015877A (es)
PE (1) PE20170427A1 (es)
PH (1) PH12016502251A1 (es)
SG (1) SG11201610221WA (es)
WO (1) WO2015185584A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3666258T3 (da) 2014-09-19 2024-02-05 Ferring Bv Fremgangsmåde til behandling af prader-willis syndrom
US20190135859A1 (en) 2017-08-11 2019-05-09 Ferring B.V. Method of manufacturing a pharmaceutical composition
AU2018312956B2 (en) 2017-08-11 2022-03-10 Ferring B.V. Method of manufacturing a pharmaceutical composition
AU2019345166B2 (en) 2018-09-20 2021-09-02 Levo Therapeutics, Inc. Stable intranasal formulations of carbetocin
JP7538802B2 (ja) 2018-09-20 2024-08-22 アカディア ファーマシューティカルズ インコーポレイテッド カルベトシン医薬品およびその製造プロセス
CN113801200B (zh) * 2021-09-28 2023-07-25 浙江湃肽生物有限公司 一种卡贝缩宫素的制备方法
WO2024044633A2 (en) * 2022-08-23 2024-02-29 Seattle Children's Hospital (D/B/A Seattle Children's Research Institute) Oxytocin derivatives and methods of use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4483794A (en) * 1983-05-10 1984-11-20 Ceskoslovenska Akademie Ved Analogs of neurohypophysial hormones
KR20070022753A (ko) * 2004-05-26 2007-02-27 화이자 인코포레이티드 인다졸 및 인돌론 유도체 및 이의 약제로서의 용도
FR2875499B1 (fr) * 2004-09-20 2006-10-27 Sanofi Aventis Sa Nouveaux derives pyridiniques d'indolin-2-one, leur preparation et leur application en therapeutique
CA2676066C (en) * 2007-01-22 2016-06-28 Gtx, Inc. Nuclear receptor binding agents
CA2718148C (en) * 2008-03-31 2017-11-07 Ferring B.V. Oxytocin analogues
EP2337783A1 (en) * 2008-09-23 2011-06-29 F. Hoffmann-La Roche AG Isoxazolo[4,5]pyridin-3-yl-piperazin derivatives useful as modulatorsof dopamine d3 receptors
CN102414204B (zh) * 2009-05-05 2014-12-31 弗·哈夫曼-拉罗切有限公司 异噁唑-哒嗪衍生物
TWI463990B (zh) * 2009-09-21 2014-12-11 Ferring Bv 催產素受體促進劑
ES2509270T3 (es) * 2009-10-01 2014-10-17 The University Of Sydney Terapia y prevención del alcoholismo
WO2012016229A2 (en) 2010-07-30 2012-02-02 The Regents Of The University Of California Oxytocin treatment to improve memory and modify blood glucose

Also Published As

Publication number Publication date
EP3152225B1 (en) 2018-11-14
EP3152225A1 (en) 2017-04-12
CN106459156A (zh) 2017-02-22
PH12016502251A1 (en) 2017-02-06
EA030296B1 (ru) 2018-07-31
JP6535688B2 (ja) 2019-06-26
MX2016015877A (es) 2017-03-27
US20170081368A1 (en) 2017-03-23
IL248625A0 (en) 2017-01-31
WO2015185584A1 (en) 2015-12-10
AU2015270564A1 (en) 2016-11-17
KR20170004014A (ko) 2017-01-10
SG11201610221WA (en) 2017-01-27
PE20170427A1 (es) 2017-04-26
EA201692488A1 (ru) 2017-05-31
CR20160562A (es) 2017-01-06
CA2950493A1 (en) 2015-12-10
JP2017518313A (ja) 2017-07-06

Similar Documents

Publication Publication Date Title
CL2016003416A1 (es) Herbicidas de piperidinona
CL2017001393S1 (es) Automovil
CL2017001185S1 (es) Automovil
GEAP202114450A (en) Anti-tigit antibodies
TWD174683S (zh) 戒指
ECSP17029371A (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CL2016002731A1 (es) Herbicidas de piridazinona
ECSP17015977A (es) Terapia de combinacion
GEAP201814347A (en) Substituted dihydroisoquinoline compounds
PL3509156T3 (pl) Roztwór elektrolitu
ES2808978T8 (es) Heteroarilamidas como inhibidores de la agregación de proteínas
DK3228731T3 (da) Oxygen-genererende anode
CL2016003076A1 (es) Péptidos como agonistas de la oxitocina
IN2015DE00625A (es)
PT3160948T (pt) Amidas benzoxazinona como moduladores de recetor de mineralocorticoide
GT201500008S (es) Botella
TWD171710S (zh) 端子
IL248553A0 (en) Peptides as oxytocin agonists
BR112017004531A2 (pt) aparelho de anodo
SE1530091A1 (es)
TWD171709S (zh) 端子
GT201500010S (es) Botella
GEAP201814327A (en) Treatment regimen tiacumicin compound
GT201400039S (es) Diseño de bici-motocicleta
TN2014000388A1 (fr) منظومة فيزيائية متجانسة كهربائية ميكانيكية مغناطيسية لتوليد الطاقة الكهربائية الحرة الايكولوجية المضاعفة